These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 28378892)

  • 21. Thyroid transcription factor-1 amplification and expressions in lung adenocarcinoma tissues and pleural effusions predict patient survival and prognosis.
    Li X; Wan L; Shen H; Geng J; Nie J; Wang G; Jia N; Dai M; Bai X
    J Thorac Oncol; 2012 Jan; 7(1):76-84. PubMed ID: 22011671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas: Comparison of four commercially available antibodies by immunohistochemistry and fluorescence in situ hybridization study.
    Lee HJ; Xu X; Choe G; Chung DH; Seo JW; Lee JH; Lee CT; Jheon S; Sung SW; Chung JH
    Lung Cancer; 2010 Jun; 68(3):375-82. PubMed ID: 19712993
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis.
    Tong JH; Yeung SF; Chan AW; Chung LY; Chau SL; Lung RW; Tong CY; Chow C; Tin EK; Yu YH; Li H; Pan Y; Chak WP; Ng CS; Mok TS; To KF
    Clin Cancer Res; 2016 Jun; 22(12):3048-56. PubMed ID: 26847053
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ROS1 copy number alterations are frequent in non-small cell lung cancer.
    Clavé S; Gimeno J; Muñoz-Mármol AM; Vidal J; Reguart N; Carcereny E; Pijuan L; Menéndez S; Taus Á; Mate JL; Serrano S; Albanell J; Espinet B; Arriola E; Salido M
    Oncotarget; 2016 Feb; 7(7):8019-28. PubMed ID: 26783962
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidermal Growth Factor Receptor Gene Amplification Predicts Worse Outcome in Patients With Surgically Resected Nonadenocarcinoma Lung Cancer.
    Chang H; Yang Y; Lee JS; Jheon SH; Kim YJ; Chung JH
    Clin Lung Cancer; 2019 Jan; 20(1):7-12.e1. PubMed ID: 30017644
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intertumor heterogeneity of non-small-cell lung carcinomas revealed by multiplexed mutation profiling and integrative genomics.
    Tan DS; Camilleri-Broët S; Tan EH; Alifano M; Lim WT; Bobbio A; Zhang S; Ng QS; Ang MK; Iyer NG; Takano A; Lim KH; Régnard JF; Tan P; Broët P
    Int J Cancer; 2014 Sep; 135(5):1092-100. PubMed ID: 24482041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation between molecular analysis, diagnosis according to the 2015 WHO classification of unresected lung tumours and TTF1 expression in small biopsies and cytology specimens from 344 non-small cell lung carcinoma patients.
    Russell PA; Rogers TM; Solomon B; Alam N; Barnett SA; Rathi V; Williams RA; Wright GM; Conron M
    Pathology; 2017 Oct; 49(6):604-610. PubMed ID: 28811082
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distinct outcome of stage I lung adenocarcinoma with ACTN4 cell motility gene amplification.
    Noro R; Honda K; Tsuta K; Ishii G; Maeshima AM; Miura N; Furuta K; Shibata T; Tsuda H; Ochiai A; Sakuma T; Nishijima N; Gemma A; Asamura H; Nagai K; Yamada T
    Ann Oncol; 2013 Oct; 24(10):2594-2600. PubMed ID: 23899839
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aberrant S100A16 expression might be an independent prognostic indicator of unfavorable survival in non-small cell lung adenocarcinoma.
    Chen D; Luo L; Liang C
    PLoS One; 2018; 13(5):e0197402. PubMed ID: 29746588
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [EGFR gene copy number, ERCC1 and BRCA1 protein expression and their relationship in non-small cell lung cancer].
    Deng QH; Qiu Y; Mo MC; Zhang X; Xiong XG; Jiang M; He P; Wen DP; Zheng GX; He JX
    Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):508-12. PubMed ID: 22093627
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy.
    Sun JM; Han J; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2011 Aug; 6(8):1392-9. PubMed ID: 21716147
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HER2 gene mutations in non-small cell lung carcinomas: concurrence with Her2 gene amplification and Her2 protein expression and phosphorylation.
    Suzuki M; Shiraishi K; Yoshida A; Shimada Y; Suzuki K; Asamura H; Furuta K; Kohno T; Tsuta K
    Lung Cancer; 2015 Jan; 87(1):14-22. PubMed ID: 25468202
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma.
    Dacic S; Flanagan M; Cieply K; Ramalingam S; Luketich J; Belani C; Yousem SA
    Am J Clin Pathol; 2006 Jun; 125(6):860-5. PubMed ID: 16690485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MET overexpression and gene amplification: prevalence, clinico-pathological characteristics and prognostic significance in a large cohort of patients with surgically resected NSCLC.
    Sterlacci W; Fiegl M; Gugger M; Bubendorf L; Savic S; Tzankov A
    Virchows Arch; 2017 Jul; 471(1):49-55. PubMed ID: 28528511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma.
    Anagnostou VK; Syrigos KN; Bepler G; Homer RJ; Rimm DL
    J Clin Oncol; 2009 Jan; 27(2):271-8. PubMed ID: 19064983
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas.
    Zhang Y; Wang R; Li Y; Pan Y; Hu H; Zhang Y; Li H; Shen L; Yu Y; Sun Y; Chen H
    J Thorac Oncol; 2015 Oct; 10(10):1444-50. PubMed ID: 26200450
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of the NEDD4L gene as a prognostic marker by integrated microarray analysis of copy number and gene expression profiling in non-small cell lung cancer.
    Sakashita H; Inoue H; Akamine S; Ishida T; Inase N; Shirao K; Mori M; Mimori K
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S590-8. PubMed ID: 23812770
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The prognostic value of chromosome 7 polysomy in non-small cell lung cancer patients treated with gefitinib.
    Buckingham LE; Coon JS; Morrison LE; Jacobson KK; Jewell SS; Kaiser KA; Mauer AM; Muzzafar T; Polowy C; Basu S; Gale M; Villaflor VM; Bonomi P
    J Thorac Oncol; 2007 May; 2(5):414-22. PubMed ID: 17473657
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
    Schneider CP; Heigener D; Schott-von-Römer K; Gütz S; Laack E; Digel W; Guschall WR; Franke A; Bodenstein H; Schmidtgen C; Reck M
    J Thorac Oncol; 2008 Dec; 3(12):1446-53. PubMed ID: 19057271
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of MCM7 expression in the bronchial brushings of patients with non-small cell lung cancer (NSCLC).
    Liu YZ; Jiang YY; Hao JJ; Lu SS; Zhang TT; Shang L; Cao J; Song X; Wang BS; Cai Y; Zhan QM; Wang MR
    Lung Cancer; 2012 Jul; 77(1):176-82. PubMed ID: 22456526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.